HubSpot Shorts Keep Covering While Analysts Grow Cautious

HUBS short sellers have been cutting positions fast ahead of Wednesday's earnings, even as the analyst community tilts more defensive than it has in months.

Short interest has fallen 14.4% over the past week to 7.3% of free float, roughly 3.82 million shares. That continues a sharper unwind: the position had climbed 28% over the prior month before reversing course from mid-October. The covering has arrived against a difficult tape. HUBS dropped 13.3% on the week to $234.87, a steeper fall than the median decline of around 4% across its closest software peers. MNDY fell 10.3% on the week, ASAN dropped 6.6%, and KVYO declined 4.6%, making HUBS the clear laggard in the group. Cost to borrow has risen 34% over the past week but remains negligible in absolute terms at 0.39%. Borrow availability is exceptionally loose at over 5,000% of short interest, meaning there are roughly 50 shares available to borrow for every one already shorted. Shorts covering into a falling stock points to position management rather than any squeeze pressure from the lending market.

The analyst picture is more fractured than usual heading into the print. Multiple firms raised price targets in the past week while keeping neutral ratings, a combination that says the stock has moved but conviction hasn't followed. UBS lifted its target to $310 while simultaneously downgrading to Neutral from Buy. Citigroup raised to $287 while holding Neutral. Barclays and JP Morgan both cut their ratings in October, each moving to Equal-Weight and Neutral respectively, on concerns about near-term demand. The bull case rests on HubSpot's AI pivot toward agentic workflows and its still-small roughly 4% market share growing at around three times the broader market rate. Bears point to the SMB-heavy customer base as a vulnerability in a tighter spending environment, and raise the risk that usage-based AI pricing could lower revenue per customer rather than expand it. The mean price target across the Street is $257.67, implying about 10% above the current price, but the distribution of views is wide and the direction of travel among the largest firms has been cautious.

Insider activity carries no particular signal this cycle. The only open-market sale in recent months was an 8,500-share disposal by director Brian Halligan in October, executed under a pre-arranged 10b5-1 plan. The remaining transactions on the register are tax-withholding entries tied to vesting, not discretionary conviction trades. On the institutional side, BlackRock added over 1.7 million shares to reach 10.4% of shares in its most recent filing, while JPMorgan Chase disclosed a 13G position at 7.3%. Neither filing signals an activist intent.

Historically, earnings have been punishing. The most recent print in August triggered a one-day drop of 18.7% and the stock was still down 15.6% five days later. A prior event in September produced a 8.6% one-day decline. Wednesday's result will test whether the recovery in the stock over the past month, up roughly 19%, reflects genuine stabilisation in demand or simply a repricing that runs ahead of what the numbers can support.